We develop and manufacture lentiviral vectors as a European leader working under both EMA and FDA standards. The lentiviral vectors produced by VIVEbiotech are used to treat a range of disorders, including haematological and solid cancers, and rare diseases.

We are a Contract Development and Manufacturing Organization (CDMO) with over 20 biotech companies worldwide that have placed their trust in us.

A solid project with its own personality

Our roots are 100% Guipuzcoan. Since 2015 we have spearheaded the creation of an ecosystem in our region specialized in health-related biotechnology aimed at personalized precision medicine.

Our stable international clients and large-scale projects allow us to consolidate our structure and continue to grow sustainably, positioning our company and our region at the forefront of the medicine of the future on a global level.

2004

Advanced Therapies Unit created.

2006

Good manufacturing practices (GMP) approved by the Spanish Agency for Medicine and Health Products (AEMPS).

2009

Lentivirus Vector Unit for use in research.

2012

UNE - EN ISO 9001-2008

2015

VIVEbiotech created.

Members of

Collaborate with

Project with a future

These are exciting times in the world of biotechnology and health, with realistic expectations for cures for many pathologies. VIVEbiotech is one of the players making this possible. In 2021 we opened a new facility with state-of-the-art equipment and capacity for clinical and commercial production phases as a stepping stone to VIVEbiotech's future strategic goals.